Login / Signup

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.

Luisa GuidiDaniela PuglieseTommaso Panici TonucciLorenzo BertaniFrancesco CostaGiuseppe PriviteraBarbara TolussoClara Di MarioEleonora AlbanoGherardo TapeteElisa GremeseAlfredo PapaAntonio GasbarriniGian Ludovico RapacciniAlessandro Armuzzi
Published in: United European gastroenterology journal (2019)
High vedolizumab trough level at week 14 was associated with a higher probability of maintaining vedolizumab therapy over the first year due to sustained clinical benefit.
Keyphrases
  • ulcerative colitis
  • patients with inflammatory bowel disease
  • randomized controlled trial
  • stem cells
  • clinical trial
  • bone marrow
  • cell therapy
  • study protocol